Overview

A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer

Status:
Active, not recruiting
Trial end date:
2023-12-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients/subjects with advanced gastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Clovis Oncology, Inc.
Treatments:
Ipilimumab
Linrodostat
Nivolumab
Rucaparib